Star Ratings, Decentralized Trials, Gene Therapy Frameworks, RWE Guidance

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, the CMS Star Ratings update has been on my mind since yesterday's announcement. The methodology shifts are going to ripple through provider contracts.

MarcusSame here. We're looking at CMS Medicare Advantage Star Ratings methodology shifts — how the new quality metrics are reshaping provider incentives. Then FDA draft guidance on decentralized clinical trials — what this means for trial design flexibility. And ICER's new framework for ultra-orphan therapies — how it addresses evidence gaps in rare diseases.

SaraThat second one is interesting to me — the decentralized trials guidance could fundamentally change how we generate real-world evidence for accelerated approvals, but the operational hurdles are significant.

MarcusExactly. Let's get into it.

MarcusStarting with CMS Medicare Advantage Star Ratings. The proposed changes include expanded quality measures for behavioral health and social determinants of health. This isn't just incremental — it's a structural shift toward holistic value assessment.

SaraThat's one read — I'd frame it slightly differently. From a payer perspective, these expanded metrics will force plans to invest in community partnerships, but the attribution models for SDOH remain murky. How do you measure 'social connection' in claims data?

MarcusFair point. CMS is piloting geosocial mapping tools, but the implementation timeline feels optimistic. What strikes me is the tension between comprehensive measurement and practical feasibility.

SaraExactly. And the budget impact here is substantial. Plans will need to reallocate resources from traditional clinical metrics to these new domains, with no clear ROI path yet.

MarcusThe part that gives me pause is the timing. With MA enrollment growing at 8% annually, these changes could accelerate value-based care adoption, but also create access disparities for plans in resource-constrained areas.

SaraThat connects to something I keep coming back to — these shifts will pressure HEOR teams to develop new evidence generation strategies for social determinants. The traditional RCT model doesn't capture these factors well.

MarcusRight. And from the payer side, the opportunity cost of investing in SDOH versus direct clinical interventions is a calculation that will define next-gen value frameworks.

SaraNow to FDA's decentralized trials guidance. The draft emphasizes electronic consent, remote monitoring, and hybrid designs. This is a clear signal to accelerate enrollment in rare and geographically dispersed populations.

MarcusI wonder if that's the full picture though. While the flexibility is welcome, the guidance lacks specifics on decentralized data integrity validation. For HEOR teams, this means real-world data from such trials may face higher evidentiary hurdles in HTA submissions.

SaraThat's fair, though I think payers would see it differently. The operational cost savings from reduced site management could lower development costs, potentially improving value propositions. But the patient burden isn't disappearing — it's shifting to digital literacy requirements.

MarcusWhat's striking here is the regulatory divergence. EMA's adaptive pathways have more mature decentralized trial frameworks, creating transatlantic evidence challenges for developers.

SaraThe part that gives me pause is the patient-reported outcomes collection in decentralized settings. How do you ensure consistent PRO measurement when participants are using different devices and interfaces?

MarcusExactly. And this is one of those stories where the innovation outpaces methodology. FDA is signaling flexibility, but HTA bodies may require additional validation layers for RWE from such trials.

SaraHonestly, this one caught me off guard — the guidance could accelerate RWE generation but may create new evidence standardization headaches. The industry will need to invest heavily in digital PRO platforms.

MarcusICER's new framework for ultra-orphan therapies addresses the evidence gap for ultra-rare conditions. The key innovation is allowing single-arm trials with historical controls when RCTs are impossible.

SaraThat's one read — I'd frame it slightly differently. The framework's emphasis on natural history data collection is crucial, but the threshold for acceptable evidence remains undefined. How do you quantify 'sufficient' evidence for ultra-rare diseases with <100 patients globally?

MarcusThe part that gives me pause is the cost-effectiveness application. By accepting lower evidence thresholds, ICER may be setting precedents for higher ICER values in ultra-orphan space, but the budget impact implications are enormous.

SaraRight, and from the payer side, this creates a two-tiered system. Ultra-orphan therapies may get more flexible pathways, but that strains system sustainability when multiple ultra-orphans emerge in the same therapeutic area.

MarcusWhat strikes me is the tension between scientific rigor and patient need. ICER is acknowledging reality, but the methodology for extrapolating from single-arm trials needs refinement.

SaraThat connects to something I keep coming back to — this framework could accelerate access but may require new value assessment models that account for extreme rarity. The opportunity cost of funding one ultra-orphan versus many common conditions becomes more acute.

MarcusExactly. And for HEOR teams, this means developing more sophisticated modeling approaches for ultra-rare disease natural history data.

SaraNICE's updated RWE guidance for technology appraisals expands acceptable evidence types beyond traditional RCTs. The key additions include real-world data from registries and pragmatic trials.

MarcusI wonder if that's the full picture though. While the expanded evidence types are welcome, the guidance lacks clear quality thresholds for RWE. This creates uncertainty for developers building evidence strategies.

SaraThat's fair, though I think payers would see it differently. The move could expedite appraisals for technologies with established safety profiles, reducing development timelines. But the methodological rigor requirements for RWE remain high.

MarcusWhat's striking here is the timing. With NICE's threshold consultation ongoing, this RWE expansion could signal broader acceptance of real-world evidence in value assessments.

SaraThe part that gives me pause is the data governance implications. Accepting RWE from multiple sources requires robust interoperability standards that the industry hasn't fully developed yet.

MarcusExactly. And this is one of those stories where the policy shift outpaces infrastructure. NICE is signaling openness, but the practical implementation will depend on data standardization efforts.

SaraHonestly, this one caught me off guard — the guidance could revolutionize evidence generation but may create new challenges in data quality assessment. HEOR teams will need to invest in RWE analytics capabilities.

SaraA lot to think about today. I'll be watching how CMS's Star Ratings implementation affects provider incentives for social determinants of health interventions.

MarcusSame — and for me the thread running through today is the growing tension between regulatory flexibility and evidentiary rigor across HTA systems. The industry needs to navigate these shifts carefully.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.